PARP1 and cervical cancer: To conclude, the present study provide evidence indicating that CpG-ODNs may attenuate RKI in cervical cancer by blocking PARP1/XRCC1 axis activation and inhibiting DNA damage and oxidative stress in renal tubular epithelial cells (Fig. 7).